MedPath

Nutritional Supplement's Effects on Cognition

Not Applicable
Recruiting
Conditions
Dietary Supplement
Cognition
Healthy
Interventions
Dietary Supplement: Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E
Dietary Supplement: Placebo
Registration Number
NCT05941949
Lead Sponsor
Pharmanex
Brief Summary

This is a prospective, placebo controlled study, examining the effects of dietary supplement's effects on cognition and confirming safety.

Detailed Description

The objective of this prospective, placebo controlled, double-blinded, parallel-group study is to examine the effects of dietary supplement containing grape juice extract, astaxanthin, and vitamin E over 12 week consumption on cognitive performance and self report results based on questionnaires. Furthermore, an evaluation of general well-being, mood, markers of oxidative stress, neurogenesis (BDNF), eye health, skin health, skin carotenoid concentrations, and safety measurements will be assessed.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
110
Inclusion Criteria
  • Health Individuals
  • Residing in independent living accommodations
  • Subjective report of memory or attention problems by answering 'yes' to the following questions: Do you have problems with your memory, attention, or concentration?
  • Non-smoker
  • Body Mass Index (BMI) between 18-35 kg/m2
  • No plan to commence new treatments over the study period
  • Understand, willing and able to comply with all study procedures
  • Willing to provide a personally signed and dated informed consent form detailing all pertinent aspects of the study
Exclusion Criteria
  • Diagnosis of dementia based on the revised National Institute on Aging-Alzheimer's Association (NIA/AA) criteria
  • A score below the 5th percentile for age, education, and gender on the Telephone Interview for Cognitive Status (TICS-M)
  • Suffering from recently diagnosed or unmanaged medical conditions including but not limited to diabetes, hyper/hypotension, cardiovascular disease, gallbladder disease, autoimmune disease, endocrine disease, or cancer/malignancy
  • Diagnosis of a psychiatric disease (other than mild-to moderate depression of anxiety) and/or neurological condition/disease (e.g. Parkinson's, Alzheimer's disease)
  • History of paralysis, stroke or seizures or head injury (with loss of consciousness)
  • Regular medication intake including but not limited to anticholinergics, acetylcholinesterase inhibiters, or steroid medications.
  • Taking vitamins or herbal supplements that are reasonably expected to influence study measures
  • In the last 6 month, commenced or changed the dose of nutritional and/or herbal supplements that may impact on treatment outcome
  • Alcohol intake greater than 14 standard drinks per week
  • Current or 12-month history of illicit drug abuse
  • Pregnant women, women who are Brest feeding, or women who intend to fall pregnant
  • Any significant surgeries over the last year
  • Planned major lifestyle change in the next 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ActiveSoftgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin ESoftgel containing: Astaxanthin, Grape Juice Extract, and All Natural Vitamin E
PlaceboPlaceboSoftgel containing: Olive Oil and Sunflower Lecithin
Primary Outcome Measures
NameTimeMethod
Change in Working memory by Corsi Block tasksBaseline and Week 12

Determine if working memory change by doing Corsi blocks task

Change in working memoryBaseline and Week 12

Determine change in working memory as measured by the Numeric Working Memory Test

Change in verbal learning and memoryBaseline and Week 12

Determine if verbal learning and memory change using total score on Rey Auditory Verbal Learning test trials 1 to 5

Change in episodic memoryBaseline and Week 12

Determine change in episodic memory as measured by Rey Auditory Verbal Learning Test delayed recall and computerized location learning task

Secondary Outcome Measures
NameTimeMethod
Change in accuracy of attentionBaseline and Week 12

Determine change inaccuracy of attention as measured by the choice reaction time and digit vigilance task (percent correct)

Change in the Perceived Stress scoreBaseline, Week 4, Week 8, Week 12

Determine the change in the Perceived Stress Questionnaire total score

Change in marker of inflammation in the plasmaBaseline and Week 12

Determine the change in the plasma marker (interleukin-6-alpha concentrations

Change in Skin Carotenoid ScoreBaseline and Week 12

Determine the change in Skin Carotenoid Scores using Raman spectroscopy (BioPhotonic Scanner)

Change in the Everyday MemoryBaseline, Week 4, Week 8, Week 12

Determine the change in the Everyday Memory Questionnaire total score

Change in the World Health Organization scoreBaseline, Week 4, Week 8, Week 12

Determine the change in the World Health Organization-5 (WHO-5) score

Change in plasma Tumor Necrosis Factor-alpha concentrationsBaseline and Week 12

Determine change in plasma Tumor Necrosis Factor concentrations

Change in plasma Brain-derived neurotropic factor concentrationsBaseline and Week 12

Determine the change in plasma Brain-derived neurotropic factor concentrations

Change in oxidative stress markerBaseline and Week 12

Determine change in plasma malondialdehyde

Trial Locations

Locations (1)

Clinical Research Australia

🇦🇺

Duncraig, Western Austrailia, Australia

© Copyright 2025. All Rights Reserved by MedPath